S*BIO Articles

MEI Pharma to acquire S*BIO's pracinostat

8 August 2012

Cell Therapeutics to acquire pacritinib, a potential myelofibrosis drug

20 April 2012

More news for ASH meeting

13 December 2011

S*BIO regains rights from Onyx for JAK2 inhibitor program; Almirall to market co-brand of Nycomed’s roflumilast in Spain

5 May 2011

S*BIO's JAK2 inhibitor SB1518 granted orphan status by European Commission for myelofibrosis

19 October 2010

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end